TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Akari Therapeutics ( (AKTX) ) has issued an announcement.
On October 14, 2025, Akari Therapeutics entered into a securities purchase agreement with institutional investors for a direct offering of 3,125,000 American Depositary Shares (ADSs) and accompanying warrants, expected to raise approximately $2.5 million. The proceeds will be used for working capital, corporate purposes, and research and development, specifically to enhance data on a novel ADC payload for cancer treatment, with the offering expected to close around October 16, 2025.
The most recent analyst rating on (AKTX) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Akari Therapeutics stock, see the AKTX Stock Forecast page.
Spark’s Take on AKTX Stock
According to Spark, TipRanks’ AI Analyst, AKTX is a Neutral.
Akari Therapeutics’ stock score of 44 reflects significant challenges due to its current financial instability and lack of revenue. While the technical analysis indicates a neutral trend, the company’s speculative nature due to the absence of traditional valuation metrics underscores the risk. However, the recent positive corporate event with the appointment of a new CEO brings some potential for strategic improvement, slightly offsetting the otherwise high-risk profile.
To see Spark’s full report on AKTX stock, click here.
More about Akari Therapeutics
Akari Therapeutics is a biopharmaceutical company focused on developing treatments for rare and orphan diseases, particularly in the area of immunotherapy and cancer research.
Average Trading Volume: 197,089
Technical Sentiment Signal: Sell
Current Market Cap: $26.74M
Find detailed analytics on AKTX stock on TipRanks’ Stock Analysis page.